Hengrui Pharmaceutical iodxaol injection application approved in Germany

recently,
theof its sub-
company(http://, Cadiasun Pharma GmbH, received a letter of approval from the German FederalPharmaceutical(http://and theResearch Institute ofMedical Devices
(http:// to approve the company's application for listing of iodxaol injections in Germany, the http://on iodxaol injection
Iodsaol injection is an X-ray contrast agent, suitable for adult cardiovascular contrast, cerebrovascular angiography (conventional), peripheral arterial imaging (routine), excretion urinary tract angiography and computer tomography (CT), can make abnormal structure or lesions development, to distinguish betweenhealthy(http://tissues and pathological tissueshis indications include lumbar, thoracic and cervical spinal imaging and gastrointestinal tract (oral and rectum) examinations, as well as cardiovascular imaging, excretion urinary tract imaging, CT enhancement and upper digestive tract examination in childreniodxaol injections developed by NorwegianPharmaceutical(http://Pharmaceuticals(http://named Iodixanol Injection, a product called VISIPAQUEThe drug was first introduced in 1994 in Sweden, the United Kingdom, Switzerland and other European countries, and is currently listed in China, the United States, Japan, France and other countries and regions